5-(2-cyclopropyl-1-(4-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl Acetate CAS 1391194-50-5

Product Description:

Product Name: 5-(2-cyclopropyl-1-(4-fluorophenyl)-2-oxoethyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate CAS NO:1391194-50-5

Synonyms:

Prasugrel Para-Fluoro Isomer;

Chemical & Physical Properties:

Appearance : White powder

Assay :≥97.0%

Density: 1.347g/cm3

Boiling Point:497.6℃at 760 mmHg

Flash Point:254.7℃

Prasugrel Impurity/Intermediate.

Prasugrel also has a stronger performance than clopidogrel in stable angina pectoris and acute coronary syndrome interventional surgery, but the stronger the antiplatelet effect, the more likely it is to cause bleeding. The key question now is how to identify patients at high risk of thrombosis in clinical practice, and how to identify people at high risk of bleeding, so that prasugrel and clopidogrel can be used differently in the two high-risk groups, which can reduce coronary thrombosis and avoid Major bleeding. On December 18, 2008, Prasugrel received its first major international approval, and the European Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency recommended approval of the drug.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.